Augmenting DAF levels in vivo ameliorates experimental autoimmune encephalomyelitis

Molecular Immunology

Volumn 46, Issue 15, 2009, Pages 2885-2891

  Li, Qing ^a,b   Huang, Danping ^a   Nacion, Kristine ^a   Bu, Hong ^b   Lin, Feng ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Autoimmunity; DAF; EAE; MOG; Myelin; T cells

Indexed keywords

COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C5A; DECAY ACCELERATING FACTOR; DECAY ACCELERATING FACTOR 1; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CELL SURFACE; COCULTURE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CULTURE MEDIUM; DEMYELINATION; DENDRITIC CELL; DISEASE SEVERITY; ERYTHROCYTE; FEMALE; GENE FUNCTION; GENE OVEREXPRESSION; HISTOPATHOLOGY; IN VIVO STUDY; INFLAMMATION; KNOCKOUT MOUSE; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPINAL CORD; TH1 CELL; TH17 CELL; TISSUE DISTRIBUTION; TRANSGENIC MOUSE; UPREGULATION; WILD TYPE;

ANIMALS; ANTIGENS, CD55; COMPLEMENT C3A; COMPLEMENT C5A; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ERYTHROCYTES; GLYCOPROTEINS; INTERFERON-GAMMA; INTERLEUKIN-17; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; OVALBUMIN; PEPTIDE FRAGMENTS; SPINAL CORD; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, HELPER-INDUCER;

MUS; MUS MUSCULUS;

EID: 68749098460     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2009.07.003     Document Type: Article

References (26)

1. An F., Li Q., Tu Z., Bu H., Chan C.C., Caspi R.R., and Lin F. DAF protects against T cell autoreactivity that leads to experimental autoimmune uveitis. Invest. Ophthalmol. Vis. Sci. (2009)
2. Barchet W., Price J.D., Cella M., Colonna M., MacMillan S.K., Cobb J.P., Thompson P.A., Murphy K.M., Atkinson J.P., and Kemper C. Complement-induced regulatory T cells suppress T-cell responses but allow for dendritic-cell maturation. Blood 107 (2006) 1497-1504
3. Choi T., Huang M., Gorman C., and Jaenisch R. A generic intron increases gene expression in transgenic mice. Mol. Cell. Biol. 11 (1991) 3070-3074
4. Farley F.W., Soriano P., Steffen L.S., and Dymecki S.M. Widespread recombinase expression using FLPeR (flipper) mice. Genesis 28 (2000) 106-110
5. Heeger P.S., Lalli P.N., Lin F., Valujskikh A., Liu J., Muqim N., Xu Y., and Medof M.E. Decay-accelerating factor modulates induction of T cell immunity. J. Exp. Med. 201 (2005) 1523-1530
6. Jimenez-Perianez A., Ojeda G., Criado G., Sanchez A., Pini E., Madrenas J., Rojo J.M., and Portoles P. Complement regulatory protein Crry/p65-mediated signaling in T lymphocytes: role of its cytoplasmic domain and partitioning into lipid rafts. J. Leukoc. Biol. 78 (2005) 1386-1396
7. Kaminski H.J., Kusner L.L., Richmonds C., Medof M.E., and Lin F. Deficiency of decay accelerating factor and CD59 leads to crisis in experimental myasthenia. Exp. Neurol. 202 (2006) 287-293
8. Kemper C., and Atkinson J.P. T-cell regulation: with complements from innate immunity. Nat. Rev. Immunol. 7 (2007) 9-18
9. Kemper C., Chan A.C., Green J.M., Brett K.A., Murphy K.M., and Atkinson J.P. Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature 421 (2003) 388-392
10. Kisseberth W.C., Brettingen N.T., Lohse J.K., and Sandgren E.P. Ubiquitous expression of marker transgenes in mice and rats. Dev. Biol. 214 (1999) 128-138
11. Lalli P.N., Strainic M.G., Lin F., Medof M.E., and Heeger P.S. Decay accelerating factor can control T cell differentiation into IFN-gamma-producing effector cells via regulating local C5a-induced IL-12 production. J. Immunol. 179 (2007) 5793-5802
12. Lalli P.N., Strainic M.G., Yang M., Lin F., Medof M.E., and Heeger P.S. Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis. Blood 112 (2008) 1759-1766
13. Lin F., Emancipator S.N., Salant D.J., and Medof M.E. Decay-accelerating factor confers protection against complement-mediated podocyte injury in acute nephrotoxic nephritis. Lab. Invest. 82 (2002) 563-569
14. Lin F., Fukuoka Y., Spicer A., Ohta R., Okada N., Harris C.L., Emancipator S.N., and Medof M.E. Tissue distribution of products of the mouse decay-accelerating factor (DAF) genes. Exploitation of a Daf1 knock-out mouse and site-specific monoclonal antibodies. Immunology 104 (2001) 215-225
15. Lin F., Kaminski H.J., Conti-Fine B.M., Wang W., Richmonds C., and Medof M.E. Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. J. Clin. Invest. 110 (2002) 1269-1274
16. Liu J., Lin F., Strainic M.G., An F., Miller R.H., Altuntas C.Z., Heeger P.S., Tuohy V.K., and Medof M.E. IFN-gamma and IL-17 production in experimental autoimmune encephalomyelitis depends on local APC-T cell complement production. J. Immunol. 180 (2008) 5882-5889
17. Liu J., Miwa T., Hilliard B., Chen Y., Lambris J.D., Wells A.D., and Song W.C. The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. J. Exp. Med. 201 (2005) 567-577
18. Longhi M.P., Sivasankar B., Omidvar N., Morgan B.P., and Gallimore A. Cutting edge: murine CD59a modulates antiviral CD4+ T cell activity in a complement-independent manner. J. Immunol. 175 (2005) 7098-7102
19. Medof M.E., Kinoshita T., and Nussenzweig V. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J. Exp. Med. 160 (1984) 1558-1578
20. Miwa T., Maldonado M.A., Zhou L., Sun X., Luo H.Y., Cai D., Werth V.P., Madaio M.P., Eisenberg R.A., and Song W.C. Deletion of decay-accelerating factor (CD55) exacerbates autoimmune disease development in MRL/lpr mice. Am. J. Pathol. 161 (2002) 1077-1086
21. Miwa T., Maldonado M.A., Zhou L., Yamada K., Gilkeson G.S., Eisenberg R.A., and Song W.C. Decay-accelerating factor ameliorates systemic autoimmune disease in MRL/lpr mice via both complement-dependent and -independent mechanisms. Am. J. Pathol. 170 (2007) 1258-1266
22. Sogabe H., Nangaku M., Ishibashi Y., Wada T., Fujita T., Sun X., Miwa T., Madaio M.P., and Song W.C. Increased susceptibility of decay-accelerating factor deficient mice to anti-glomerular basement membrane glomerulonephritis. J. Immunol. 167 (2001) 2791-2797
23. Spiller O.B., Harris C.L., and Morgan B.P. Efficient generation of monoclonal antibodies against surface-expressed proteins by hyperexpression in rodent cells. J. Immunol. Methods 224 (1999) 51-60
24. Strainic M.G., Liu J., Huang D., An F., Lalli P.N., Muqim N., Shapiro V.S., Dubyak G.R., Heeger P.S., and Medof M.E. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity 28 (2008) 425-435
25. Sun X., Funk C.D., Deng C., Sahu A., Lambris J.D., and Song W.C. Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 628-633
26. Zambrowicz B.P., Imamoto A., Fiering S., Herzenberg L.A., Kerr W.G., and Soriano P. Disruption of overlapping transcripts in the ROSA beta geo 26 gene trap strain leads to widespread expression of beta-galactosidase in mouse embryos and hematopoietic cells. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 3789-3794